Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | NTRK1 fusion |
| Therapy | Larotrectinib |
| Indication/Tumor Type | gastrointestinal system cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NTRK1 fusion | gastrointestinal system cancer | predicted - sensitive | Larotrectinib | Phase I | Actionable | In a combined analysis of 3 clinical trials, Vitrakvi (larotrectinib) treatment resulted in an objective response rate of 75% (8/12, 1 complete response, 7 partial responses) in patients with gastrointestinal system malignancies harboring NTRK fusions, including colon cancer, pancreatic carcinoma, cholangiocarcinoma and GIST, and stable disease in 3 patients, with duration of response ranging from 3.5 to 22.9 months (Annals of Oncology, Volume 29, Issue suppl_5; NCT02122913, NCT02637687, and NCT02576431). | detail... |
| NTRK1 fusion | gastrointestinal system cancer | predicted - sensitive | Larotrectinib | Phase II | Actionable | In a Phase II trial (NAVIGATE), Vitrakvi (larotrectinib) treatment resulted in an overall response rate (ORR) of 28% (12/43, 3 complete and 9 partial responses) and stable disease in 44% (19/43) of gastrointestinal cancer patients harboring NTRK fusions, with a median duration of response of 27 mo, median progression-free survival of 6 mo, and median overall survival of 13 mo; ORR was 38% (10/26) in patients with NTRK1 fusions (PMID: 40068370; NCT02576431). | 40068370 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| O-020 - Activity of larotrectinib in patients with TRK fusion GI malignancies | Full reference... | |
| (40068370) | Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. | Full reference... |